The Knight Cancer Institute at OHSU Hospital ranks 27th in the nation, out of 850 ranked “cancer hospitals,” based on patient outcomes, operational structure and process, expert opinion, patient experience and transparency, according to U.S. News & World Report’s 2025-2026 ranking.

Angela Sklenka, MHR, has been appointed executive vice president and chief people officer of OHSU, effective Sept. 15.

In a Healio story about new research revealing that applying a daily emollient on infants younger than 9 weeks of age reduced the risk for atopic dermatitis by 16% by the time they turned 2, Eric Simpson, M.D., says, “It is an exciting finding that suggests that AD, or what primary care clinicians call AD, may be prevented by regular emollient use from birth.”

KGW-TV reports that OHSU is the first hospital in Oregon to offer treatment for certain types of prostate cancer using a robotic-assisted high-intensity focused ultrasound device. Sudhir Isharwal, M.D., says, “There are no cuts. There are no incisions to heal from. So patients feel that they did not have any major surgery, but they are able to resume their life pretty quickly.”

A collaboration of OHSU and three other universities publishes new findings in the journal Cell with broad implications across cancer-related specialties. Laura Heiser, Ph.D., says, “This research gives us a tool to begin to predict multicellular behavior.”

A collaboration of OHSU and three other universities publishes new findings in the journal Cell with broad implications across cancer-related specialties. Laura Heiser, Ph.D., says, “This research gives us a tool to begin to predict multicellular behavior.”

Mark Slifka, Ph.D., is interviewed by OPB-Radio about a review suggesting it’s not necessary for adults to get a routine vaccination booster for tetanus and diphtheria as long as childhood vaccination rates remain strong. He says, “By vaccinating the kids and maintaining high vaccination coverage, we can reduce the number of vaccines later on. So, in many ways, it’s a win-win.”

New OHSU research in nonhuman primates that suggests long COVID may be far more common in people than currently estimated. Charles Roberts, Ph.D., says, “The severity of your initial bout with COVID would not necessarily predict your chances of having long COVID down the road.”

A KGW-TV story features OHSU’s use of a noninvasive robotic device to administer high-frequency, focused ultrasound waves to destroy prostate cancer; Sudhir Isharwal, M.D., says: “What this technology does is it uses sound waves to treat and heat up the prostate cancer tissue to destroy the prostate cancer. There are no cuts. There are no incisions to heal from. So, patients feel that they did not have any major surgery, but they are able to resume their life pretty quickly.”

The Michigan Daily reports on new research led by Zheng Xia, Ph.D., and a collaborator at the University of Michigan that identifies a specific set of genes associated with extreme non-response to a common prostate cancer drug.